Engineering metabolic pathways in Escherichia coli for constructing a “microbial chassis” for biochemical production

Matsumoto, Takuya; Tanaka, Tsutomu; Kondo, Akihiko

doi:10.1016/j.biortech.2017.05.008

Cited by 51 publications

(22 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MVA pathway is a popular tool used in synthetic biology, particularly for the engineering of biofuels [40,41] and for the production of terpenoids for use in the chemical synthesis of complex compounds, including the antimalarial compound artemisinin [27]. E. coli has proven to be a workhorse for isoprenoid production and often the six-enzyme yeast MVA pathway is used to produce high levels of IPP for further modification [42]. In these MVA systems, the E. coli IPP isomerase typically has to be overexpressed to balance the IPP/DMAPP ratio [27] and avoid IPP toxicity [43].…”

Section: Discussionmentioning

confidence: 99%

A mevalonate bypass system facilitates elucidation of plastid biology in malaria parasites

et al. 2020

View full text Add to dashboard Cite

Malaria parasites rely on a plastid organelle for survival during the blood stages of infection. However, the entire organelle is dispensable as long as the isoprenoid precursor, isopentenyl pyrophosphate (IPP), is supplemented in the culture medium. We engineered parasites to produce isoprenoid precursors from a mevalonate-dependent pathway, creating a parasite line that replicates normally after the loss of the apicoplast organelle. We show that carbon-labeled mevalonate is specifically incorporated into isoprenoid products, opening new avenues for researching this essential class of metabolites in malaria parasites. We also show that essential apicoplast proteins, such as the enzyme target of the drug fosmidomycin, can be deleted in this mevalonate bypass parasite line, providing a new method to determine the roles of other important apicoplast-resident proteins. Several antibacterial drugs kill malaria parasites by targeting basic processes, such as transcription, in the organelle. We used metabolomic and transcriptomic methods to characterize parasite metabolism after azithromycin treatment triggered loss of the apicoplast and found that parasite metabolism and the production of apicoplast proteins is largely unaltered. These results provide insight into the effects of apicoplast-disrupting drugs, several of which have been used to treat malaria infections in humans. Overall, the mevalonate bypass system provides a way to probe essential aspects of apicoplast biology and study the effects of drugs that target apicoplast processes.

show abstract

Section: Discussionmentioning

confidence: 99%

A mevalonate bypass system facilitates elucidation of plastid biology in malaria parasites

et al. 2020

View full text Add to dashboard Cite

show abstract

“…E. coli is a typical and well-studied model microorganism with several advantages for heterologous protein expression, such as a clear genetic background, short culture cycle, low production cost, robustness, and easy handling. 19 In addition, our previous study 20 successfully demonstrated the functional expression of plant-derived enzymes involved in caffeine synthesis in E. coli. Therefore, these factors render E. coli a suitable host for caffeine production.…”

Section: Introductionmentioning

confidence: 98%

Engineering a novel biosynthetic pathway in Escherichia coli for the production of caffeine

Sun

Pan

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Such metabolic engineering strategies, recently reviewed by Matsumoto et al . (), not only encompass the manipulation of target structural genes but also global regulators of metabolism, such as the ArcAB two‐component system (Bidart et al ., ). These platform E .…”

Section: Bacterial Species Adopted As a Chassis: From Historical Exammentioning

confidence: 97%

Chasing bacterial chassis for metabolic engineering: a perspective review from classical to non‐traditional microorganisms

Calero

Nikel

2018

Microbial Biotechnology

209

184

View full text Add to dashboard Cite

The last few years have witnessed an unprecedented increase in the number of novel bacterial species that hold potential to be used for metabolic engineering. Historically, however, only a handful of bacteria have attained the acceptance and widespread use that are needed to fulfil the needs of industrial bioproduction - and only for the synthesis of very few, structurally simple compounds. One of the reasons for this unfortunate circumstance has been the dearth of tools for targeted genome engineering of bacterial chassis, and, nowadays, synthetic biology is significantly helping to bridge such knowledge gap. Against this background, in this review, we discuss the state of the art in the rational design and construction of robust bacterial chassis for metabolic engineering, presenting key examples of bacterial species that have secured a place in industrial bioproduction. The emergence of novel bacterial chassis is also considered at the light of the unique properties of their physiology and metabolism, and the practical applications in which they are expected to outperform other microbial platforms. Emerging opportunities, essential strategies to enable successful development of industrial phenotypes, and major challenges in the field of bacterial chassis development are also discussed, outlining the solutions that contemporary synthetic biology-guided metabolic engineering offers to tackle these issues.

show abstract

Engineering metabolic pathways in Escherichia coli for constructing a “microbial chassis” for biochemical production

Cited by 51 publications

References 65 publications

A mevalonate bypass system facilitates elucidation of plastid biology in malaria parasites

A mevalonate bypass system facilitates elucidation of plastid biology in malaria parasites

Engineering a novel biosynthetic pathway in Escherichia coli for the production of caffeine

Chasing bacterial chassis for metabolic engineering: a perspective review from classical to non‐traditional microorganisms

Contact Info

Product

Resources

About